PATENT CLAIM ANALYSIS

Application Number: 15865950
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-09
Patent Classification: ["514", "001900"]

Abstract:
We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of: SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell.

Claim (Index 16):
A method for the treatment, prophylaxis or alleviation of an ELABELA associated condition selected from the group consisting of:\n (a) cardiac dysfunction, or a cardiovascular anomaly in blood pressure, cardiac contractility or fluid balance; (b) a cardiovascular disease selected from cardiac hypertrophy, coronary artery disease (CAD), atherosclerosis, post-infarct treatment, myocardial ischemia-reperfusion injury or atrial fibrillation, coronary heart disease, heart failure; and (c) angina or congestive heart failure, the method comprising administering a therapeutically effective amount of the ELABELA polypeptide selected from the group consisting of polypeptides of SEQ ID NOs: 2 to 18.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.61538
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14496600', '15101304', '12221824', '15038202', '14717914']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7240575644723252
- 35 USC 102 Novelty (BERT): 0.5539499732883016
- Combined Prediction Score: 0.7070468053539228
- Mean Citation Score: 291.781554
- Max Citation Score: 443.47098
- Similarity Product: 252.70695435177325

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test